Products for Research Use Only
RegisterLogin

LLL3

CAT: 0804-HY-124843-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-124843-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
LLL3 (CLT-005) is a STAT3 inhibitor. LLL3 inhibits dimerization and phosphorylation of STAT3, thereby preventing intraconuclear transfer of STAT3 and inhibits the expression of STAT3 dependent genes, which encode proteins such as Bcl-xL and cyclin D1. In addition, LLL3 can induce cell growth inhibition and apoptosis in human breast cancer and rhabdomyosarcoma cells via the caspase pathway. LLL3 can be used in the study of STAT3 persistent activation types of cancer[1][2].
CAS Number
63972-38-3
Product Name Alternative
CLT-005
UNSPSC
12352005
Target
Apoptosis; STAT
Type
Reference compound
Related Pathways
Apoptosis; JAK/STAT Signaling; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/lll3.html
Concentration
10mM
Purity
97.20
Solubility
DMSO : 20 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C1C2=C(C(O)=CC=C2)C(C3=CC=CC(C(C)=O)=C13)=O
Molecular Formula
C16H10O4
Molecular Weight
266.25
References & Citations
[1]Fuh B, et al. LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model[J]. British journal of cancer, 2009, 100 (1) : 106-112.|[2]Lavecchia A, et al. Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literature[J]. Expert opinion on therapeutic patents, 2014, 24 (4) : 383-400.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Alternative Products

CatalogName
T68951-01LLL3

Popular Products